Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA II: Priority Reviews Considered For Some ANDAs

This article was originally published in The Pink Sheet Daily

Executive Summary

New pathway could restart argument between industry and FDA over what qualifies for expedited review.


Related Content

Generic Priority Review Expanded In Senate User Fee Bill
First Generic Approvals Decline For Fourth Straight Year At US FDA
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
GDUFA II: FDA Prefers A ‘Manageable Number of High-Impact Changes’
Copaxone And Complex Generics: Difficult-To-Copy Does Not Mean Impossible
ANDA Expedited Review Criteria MaPPed Out By FDA Generic Drug Office





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts